U.S. markets close in 6 hours 20 minutes
  • S&P 500

    4,597.95
    -64.90 (-1.39%)
     
  • Dow 30

    35,378.52
    -533.29 (-1.48%)
     
  • Nasdaq

    14,605.93
    -287.83 (-1.93%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    84.72
    +0.90 (+1.07%)
     
  • Gold

    1,815.70
    -0.80 (-0.04%)
     
  • Silver

    23.42
    +0.51 (+2.21%)
     
  • EUR/USD

    1.1368
    -0.0043 (-0.3751%)
     
  • 10-Yr Bond

    1.8400
    +0.0680 (+3.84%)
     
  • Vix

    21.65
    +1.34 (+6.60%)
     
  • GBP/USD

    1.3588
    -0.0059 (-0.4321%)
     
  • USD/JPY

    114.5810
    +0.0010 (+0.0009%)
     
  • BTC-USD

    41,393.77
    -1,298.27 (-3.04%)
     
  • CMC Crypto 200

    989.37
    -20.01 (-1.98%)
     
  • FTSE 100

    7,562.57
    -48.66 (-0.64%)
     
  • Nikkei 225

    28,257.25
    -76.27 (-0.27%)
     

Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Co-Founder, President and Chief Executive Officer, and Carl Morris, PhD, Chief Scientific Officer, will participate in a fireside chat at the Jefferies Gene Therapy/Editing Summit on Thursday, October 28, 2021 at 2:00 p.m. ET.

A live webcast of this fireside chat will be available on the Company’s investor relations website, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the event.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Caitlin Lowie
Solid Bio
607-423-3219
clowie@solidbio.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com